These findings warrant future randomized controlled trials to confirm the cardioprotective effects of SGLT2 inhibitors in cancer patients with and without diabetes and to evaluate their safety and efficacy in specific cancer types and treatment regimens. The gene discussed is SLC5A2; the disease is cancer.